Adamas Pharmaceuticals Company Profile (NASDAQ:ADMS)

About Adamas Pharmaceuticals

Adamas Pharmaceuticals logoAdamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMS
  • CUSIP:
Key Metrics:
  • Previous Close: $17.09
  • 50 Day Moving Average: $16.69
  • 200 Day Moving Average: $15.64
  • 52-Week Range: $21,982,000.00 - $12.02
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.67
  • P/E Growth: -0.07
  • Market Cap: $379.85B
  • Outstanding Shares: 21,982,000
  • Beta: 0.72
Profitability:
  • Net Margins: -5,267.99%
  • Return on Equity: -38.31%
  • Return on Assets: -35.25%
Debt:
  • Current Ratio: 8.79%
  • Quick Ratio: 8.79%
Additional Links:
Companies Related to Adamas Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Adamas Pharmaceuticals (NASDAQ:ADMS) (?)
Ratings Breakdown: 7 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $30.50 (76.50% upside)

Analysts' Ratings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Show:
DateFirmActionRatingPrice TargetDetails
1/5/2017MizuhoReiterated RatingBuy$26.00View Rating Details
11/6/2016JMP SecuritiesReiterated RatingBuyView Rating Details
7/25/2016Credit Suisse GroupReiterated RatingBuy$21.00View Rating Details
7/22/2016Noble FinancialReiterated RatingBuy$25.00View Rating Details
7/20/2016Needham & Company LLCReiterated RatingBuy$38.00View Rating Details
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$44.00View Rating Details
5/12/2016Cowen and CompanyReiterated RatingBuyView Rating Details
1/26/2016AegisReiterated RatingBuyView Rating Details
9/11/2015William BlairReiterated RatingOutperform$35.00View Rating Details
(Data available from 2/19/2015 forward)

Earnings

Earnings History for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2017($0.80)N/AView Earnings Details
11/3/2016($0.83)($0.66)$0.26 million$0.14 millionViewN/AView Earnings Details
5/10/2016Q1($0.76)($0.65)ViewN/AView Earnings Details
2/23/2016Q4($0.81)($0.58)ViewN/AView Earnings Details
8/11/2015Q215($0.72)($0.78)ViewN/AView Earnings Details
5/13/2015Q414($0.74)($0.69)ViewN/AView Earnings Details
3/3/2015$0.64$0.50ViewN/AView Earnings Details
11/4/2014Q314($0.44)($0.57)ViewN/AView Earnings Details
8/7/2014Q214$0.81$0.88$18.75 million$25.15 millionViewN/AView Earnings Details
5/13/2014Q114($0.09)($0.67)$30.60 million$0.18 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Adamas Pharmaceuticals (NASDAQ:ADMS)
Current Year EPS Consensus Estimate: $-3.13 EPS
Next Year EPS Consensus Estimate: $-3.05 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.61)($0.61)($0.61)
Q2 20161($0.71)($0.71)($0.71)
Q3 20161($0.88)($0.88)($0.88)
Q4 20161($0.90)($0.90)($0.90)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Adamas Pharmaceuticals (NASDAQ:ADMS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Adamas Pharmaceuticals (NASDAQ:ADMS)
Insider Ownership Percentage: 31.79%
Institutional Ownership Percentage: 75.44%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/16/2016Ix Lp MdvMajor ShareholderBuy62,977$16.48$1,037,860.96View SEC Filing  
9/13/2016Ix Lp MdvMajor ShareholderBuy84,376$15.58$1,314,578.08View SEC Filing  
9/7/2016William W EricsonDirectorBuy60,846$15.68$954,065.28View SEC Filing  
9/6/2016Ix Lp MdvMajor ShareholderBuy50,919$14.79$753,092.01View SEC Filing  
9/6/2016William W EricsonDirectorBuy7,200$15.00$108,000.00View SEC Filing  
9/2/2016William W EricsonDirectorBuy43,719$14.75$644,855.25View SEC Filing  
4/18/2016Natalie McclureSVPSell36,000$18.50$666,000.00View SEC Filing  
12/7/2015Ivan M LieberburgDirectorSell3,000$16.23$48,690.00View SEC Filing  
10/5/2015Ivan M LieberburgDirectorSell3,000$16.75$50,250.00View SEC Filing  
9/8/2015Ivan M LieberburgDirectorSell3,000$19.13$57,390.00View SEC Filing  
7/6/2015Ivan M LieberburgDirectorSell3,000$25.91$77,730.00View SEC Filing  
6/5/2015Natalie McclureSVPSell2,000$18.95$37,900.00View SEC Filing  
5/18/2015Ix Lp MdvMajor ShareholderSell1,643$18.04$29,639.72View SEC Filing  
5/15/2015Richard H BoothDirectorSell1,000$17.85$17,850.00View SEC Filing  
5/14/2015Gregory T WentCEOSell2,728$18.00$49,104.00View SEC Filing  
4/23/2015Gregory T WentCEOSell3,300$18.00$59,400.00View SEC Filing  
4/21/2015Gregory T WentCEOSell962$18.01$17,325.62View SEC Filing  
4/20/2015Gregory T WentCEOSell2,610$18.00$46,980.00View SEC Filing  
4/15/2015Richard H BoothDirectorSell1,000$17.72$17,720.00View SEC Filing  
4/14/2015Gregory T WentCEOSell14,757$7.15$105,512.55View SEC Filing  
4/10/2015William W EricsonDirectorSell37,078$18.56$688,167.68View SEC Filing  
4/6/2015Ivan M LieberburgDirectorSell3,000$17.44$52,320.00View SEC Filing  
4/6/2015Natalie McclureSVPSell2,000$17.44$34,880.00View SEC Filing  
3/19/2015Gregory T WentCEOSell23,088$18.00$415,584.00View SEC Filing  
3/18/2015Ix Lp MdvMajor ShareholderSell11,723$18.02$211,248.46View SEC Filing  
3/16/2015Richard H BoothDirectorSell1,000$17.36$17,360.00View SEC Filing  
3/13/2015Aeris Capital Equity InvestmenMajor ShareholderSell350,000$17.23$6,030,500.00View SEC Filing  
2/17/2015Richard H BoothDirectorSell1,000$16.54$16,540.00View SEC Filing  
2/5/2015Natalie McclureSVPSell2,000$16.87$33,740.00View SEC Filing  
2/2/2015Ivan M LieberburgDirectorSell3,000$16.77$50,310.00View SEC Filing  
1/5/2015Ivan M LieberburgDirectorSell3,000$17.59$52,770.00View SEC Filing  
1/5/2015Natalie McclureSVPSell2,000$17.59$35,180.00View SEC Filing  
12/24/2014Richard H BoothDirectorSell2,000$17.51$35,020.00View SEC Filing  
12/3/2014Aeris Capital Equity InvestmenMajor ShareholderSell111,625$14.51$1,619,678.75View SEC Filing  
12/1/2014Aeris Capital Equity InvestmenMajor ShareholderSell13,615$14.54$197,962.10View SEC Filing  
12/1/2014Natalie McclureSVPSell20,000$14.50$290,000.00View SEC Filing  
11/26/2014Aeris Capital Equity InvestmenMajor ShareholderSell12,500$14.77$184,625.00View SEC Filing  
11/25/2014Aeris Capital Equity InvestmenMajor ShareholderSell10,000$14.85$148,500.00View SEC Filing  
4/15/2014William W EricsonDirectorBuy300,000$16.00$4,800,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Adamas Pharmaceuticals (NASDAQ:ADMS)
DateHeadline
investingnews.com logoAdamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis (NASDAQ:ADMS)
investingnews.com - February 18 at 3:18 PM
finance.yahoo.com logoAdamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis ... - Yahoo Finance (NASDAQ:ADMS)
finance.yahoo.com - February 17 at 3:29 PM
News IconWhat are Analysts Expecting for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Earnings? - Aiken Advocate (NASDAQ:ADMS)
aikenadvocate.com - February 17 at 3:29 PM
einnews.com logoResults from Phase 2 proof-of-concept trial suggest treatment effect, warranting further development of ADS-5102 (NASDAQ:ADMS)
www.einnews.com - February 17 at 9:41 AM
us.rd.yahoo.com logoAdamas to Present New ADS-5102 Data from Phase 2 Trial in Walking Impairment Associated with Multiple Sclerosis at ACTRIMS Forum 2017 (NASDAQ:ADMS)
us.rd.yahoo.com - February 17 at 9:41 AM
News IconAs Adamas Pharmaceuticals INC (ADMS) Valuation Rose, Aeris Capital Holding Gmbh Cut Position - The Randolph Guide (NASDAQ:ADMS)
randolphguide.com - February 1 at 3:25 PM
News IconChecking the Levels on Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - The Tribune (NASDAQ:ADMS)
lakecitytribune.com - January 30 at 3:31 PM
News IconAre Insiders Bumping Up Their Positions in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Wall Street Beacon (NASDAQ:ADMS)
wsbeacon.com - January 30 at 3:31 PM
News IconVolatility Watch on Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Gilbert Daily (NASDAQ:ADMS)
gilbertdaily.com - January 30 at 1:21 AM
News IconStock Tracker: Earnings & Estimates for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Aiken Advocate (NASDAQ:ADMS)
aikenadvocate.com - January 29 at 3:17 PM
News IconCowen and Company Reaffirms "Market Perform" Rating for Merrimack Pharmaceuticals, Inc. (MACK) (NASDAQ:ADMS)
myhealthbowl.com - January 27 at 9:45 PM
News IconInvestors are Keeping Tabs on Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - The Tribune (NASDAQ:ADMS)
lakecitytribune.com - January 27 at 3:43 PM
News IconWhat are Research Firms Saying About Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? - Aiken Advocate (NASDAQ:ADMS)
aikenadvocate.com - January 27 at 3:43 PM
News IconAs Adamas Pharmaceuticals INC Cmn (ADMS) Market Valuation Rose, Shareholder Great Point Partners LLC Lifted by $7.88 Million Its Stake (NASDAQ:ADMS)
randolphguide.com - January 24 at 8:40 PM
News IconTop Rated Stock With Earnings Growth & Implied Upside: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Prospect Journal (NASDAQ:ADMS)
prospectjournal.com - January 23 at 8:24 PM
News IconWhat The Charts Are Saying About Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - The Tribune (NASDAQ:ADMS)
lakecitytribune.com - January 23 at 8:24 PM
News IconWhat is the Street Saying About Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)? - Aiken Advocate (NASDAQ:ADMS)
aikenadvocate.com - January 20 at 3:23 PM
capitalcube.com logoAdamas Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ADMS) : January 20, 2017 (NASDAQ:ADMS)
www.capitalcube.com - January 20 at 3:23 PM
capitalcube.com logoAdamas Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ADMS-US : January 19, 2017 (NASDAQ:ADMS)
www.capitalcube.com - January 19 at 3:34 PM
News IconTracking Corporate Insiders: What Are They Doing With Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Wall Street Beacon (NASDAQ:ADMS)
wsbeacon.com - January 17 at 3:51 PM
News IconAdamas Pharmaceuticals Inc ADMS Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:ADMS)
www.bioportfolio.com - January 14 at 1:40 AM
News IconRating Sentiment of The Day: Are Analysts Bearish Adamas Pharmaceuticals Inc (NASDAQ:ADMS) After Last Week? - Fair View Times (NASDAQ:ADMS)
fairviewtimes.com - January 13 at 8:38 PM
finance.yahoo.com logoAdamas Pharmaceuticals (ADMS) in Focus: Stock Up 5.4% (NASDAQ:ADMS)
finance.yahoo.com - January 9 at 3:33 PM
insidermonkey.com logoAdamas Pharmaceuticals Inc (ADMS) Is Up On PDUFA: What’s Next? (NASDAQ:ADMS)
www.insidermonkey.com - January 9 at 3:33 PM
globenewswire.com logoAdamas Outlines Key 2017 Priorities and Highlights 2016 ... - GlobeNewswire (press release) (NASDAQ:ADMS)
globenewswire.com - January 9 at 2:08 AM
finance.yahoo.com logoAdamas Outlines Key 2017 Priorities and Highlights 2016 Achievements (NASDAQ:ADMS)
finance.yahoo.com - January 8 at 8:21 PM
investingnews.com logoAdamas Announces USFDA Acceptance of New Drug Application for Levodopa-induced Dyskinesia in Patients with Parkinson’s Disease (NASDAQ:ADMS)
investingnews.com - January 7 at 8:25 PM
streetinsider.com logoAdamas Pharma (ADMS) FDA Accepts NDA for ADS-5102 (NASDAQ:ADMS)
www.streetinsider.com - January 7 at 8:25 PM
marketexclusive.com logoAnalyst Activity – Mizuho Reiterates Buy on Adamas Pharmaceuticals (NASDAQ:ADMS) (NASDAQ:ADMS)
marketexclusive.com - January 7 at 8:25 PM
us.rd.yahoo.com logo9:00 am Adamas Pharmaceuticals announces U.S. FDA acceptance of ADS-5102 new drug application for the treatment of levodopa-induced dyskinesia in patients with parkinson's disease (NASDAQ:ADMS)
us.rd.yahoo.com - January 7 at 8:25 PM
streetinsider.com logoAdamas Pharma (ADMS) FDA Accepts NDA for ADS-5102 - StreetInsider.com (NASDAQ:ADMS)
www.streetinsider.com - January 6 at 8:28 PM
globenewswire.com logoAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug ... - GlobeNewswire (press release) (NASDAQ:ADMS)
globenewswire.com - January 6 at 3:26 PM
publicnow.com logoAdamas Announces U.S. FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with Parkinson's Disease (NASDAQ:ADMS)
www.publicnow.com - January 6 at 3:26 PM
streetinsider.com logoMizuho Securities Remains Bullish on Adamas Pharma (ADMS) Following Phase I Safety Trial - StreetInsider.com (NASDAQ:ADMS)
www.streetinsider.com - January 5 at 3:37 PM
streetinsider.com logoAdamas Pharma (ADMS) Completes Phase 1 Trial of ADS-4101 to Treat Partial Onset Seizures - StreetInsider.com (NASDAQ:ADMS)
www.streetinsider.com - January 3 at 8:41 PM
finance.yahoo.com logo4:55 pm Adamas Pharmaceuticals completes Phase 1 clinical trial of ADS-4101 for treatment of partial onset seizures in patients with epilepsy (NASDAQ:ADMS)
finance.yahoo.com - January 3 at 8:41 PM
publicnow.com logoAdamas Pharmaceuticals Completes Phase 1 Clinical Trial of ADS-4101 for Treatment of Partial Onset Seizures in Patients with Epilepsy (NASDAQ:ADMS)
www.publicnow.com - January 3 at 8:41 PM
News IconAdamas Pharmaceuticals Inc.(ADMS) stock slips, “Buy” rating reiterated at Mizuho - BNB Daily (blog) (NASDAQ:ADMS)
www.baseball-news-blog.com - January 1 at 3:20 PM
News IconAdamas Pharmaceuticals, Inc. (ADMS) Valuation According To ... - UK Market News (NASDAQ:ADMS)
www.ukmarketnews.co.uk - December 30 at 3:20 PM
finance.yahoo.com logoMylan (MYL) Announces Multiple Generic Launches in the U.S. (NASDAQ:ADMS)
finance.yahoo.com - December 30 at 3:20 PM
investornewswire.com logoSentiments And Ratings Alert: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - December 27 at 5:45 AM
News IconGrowth Story Unfolding for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Prospect Journal (NASDAQ:ADMS)
prospectjournal.com - December 27 at 5:45 AM
investornewswire.com logoAdamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Strong Sell Recommendations At 0 - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - December 23 at 3:24 PM
News IconTop Stock With Upside & Growth Potential: Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - Prospect Journal (NASDAQ:ADMS)
prospectjournal.com - December 20 at 8:15 PM
investornewswire.com logoStrong Sell Recommendations Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) At 0 - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - December 16 at 8:29 PM
News IconTrading Focus: Checking ATR Levels for Adamas Pharmaceuticals Inc. (ADMS) - StockTalk Daily (NASDAQ:ADMS)
stocktalkdaily.com - December 16 at 3:26 PM
insidermonkey.com logoIs Craft Brew Alliance Inc (BREW) A Good Stock To Buy? (NASDAQ:ADMS)
www.insidermonkey.com - December 13 at 3:20 PM
News IconWhat The Charts Are Saying About Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) - The Business Journal (NASDAQ:ADMS)
belmontbusinessjournal.com - December 12 at 3:25 PM
investornewswire.com logoCan Shares Of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Hit $45? - Investor Newswire (NASDAQ:ADMS)
www.investornewswire.com - December 9 at 8:25 PM
insidermonkey.com logoIs Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy? (NASDAQ:ADMS)
www.insidermonkey.com - December 8 at 3:29 PM

Social

What is Adamas Pharmaceuticals' stock symbol?

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Where is Adamas Pharmaceuticals' stock going? Where will Adamas Pharmaceuticals' stock price be in 2017?

7 brokerages have issued 12-month price targets for Adamas Pharmaceuticals' shares. Their forecasts range from $21.00 to $44.00. On average, they anticipate Adamas Pharmaceuticals' stock price to reach $30.50 in the next year.

When will Adamas Pharmaceuticals announce their earnings?

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 21st 2017.

Who owns Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (12.44%), Brenner West Capital Advisors LP (5.56%), Armistice Capital LLC (2.44%), State Street Corp (1.17%), FIL Ltd (0.82%) and Dimensional Fund Advisors LP (0.58%). Company insiders that own Adamas Pharmaceuticals stock include Aeris Capital Equity Investmen, Gregory T Went, Ivan M Lieberburg, Ix Lp Mdv, Natalie Mcclure, Richard H Booth and William W Ericson.

Who sold Adamas Pharmaceuticals stock? Who is selling Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates, Bingham Osborn & Scarborough LLC, J. Goldman & Co LP and Allianz Asset Management AG.

Who bought Adamas Pharmaceuticals stock? Who is buying Adamas Pharmaceuticals stock?

Adamas Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Armistice Capital LLC, Brenner West Capital Advisors LP, Dimensional Fund Advisors LP, Russell Investments Group Ltd. and State Street Corp. Company insiders that have bought Adamas Pharmaceuticals stock in the last two years include Ix Lp Mdv and William W Ericson.

How do I buy Adamas Pharmaceuticals stock?

Shares of Adamas Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Adamas Pharmaceuticals stock cost?

One share of Adamas Pharmaceuticals stock can currently be purchased for approximately $17.28.

Adamas Pharmaceuticals (NASDAQ:ADMS) Chart for Sunday, February, 19, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Earnings History Chart

Earnings by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Dividend History Chart

Dividend Payments by Quarter for Adamas Pharmaceuticals (NASDAQ:ADMS)

Last Updated on 2/19/2017 by MarketBeat.com Staff